Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Analyst: G1 Minimizes the Carnage of Chemotherapy

Streetwise Reports, Streetwise Reports
0 Comments| July 2, 2020

{{labelSign}}  Favorites

ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA.

Click to enlarge

In a June 26 research note, analyst Tony Butler reported that ROTH Capital Partners initiated coverage on G1 Therapeutics Inc. (GTHX:NASDAQ) with a Buy rating and a $55 per share price target. The stock is currently trading at about $24.28 per share.

Butler reviewed the status of the oncology therapeutics firm's three primary candidates.

G1's lead drug is trilaciclib, for which it is currently filing a new drug application (NDA) with the U.S. Food and Drug Administration for its use in nonsmall cell lung cancer. The company is expected to complete the application in Q2/20 and commercially launch the therapeutic next year.

For the use of trilaciclib in that indication in the U.S., ROTH models a 75% chance of approval and if approved, peak sales of $500 million. In triple-negative breast cancer, ROTH models $500 million of peak sales and in colorectal cancer, $600 million, both with market entry in 2025-2026.

Butler described trilaciclib as a "CDK4/6 inhibitor that transiently halts cell cycle progression in the bone marrow to ameliorate chemo-induced toxicities. "The primary conclusion from the pooled data support that trilaciclib prior to chemotherapy significantly reduced chemotherapy-induced myelosuppression and was associated with a substantial reduction in high grade hematological treatment-emergent adverse events with no detrimental effects on progression-free survival [PFS] or overall survival [OS]. However, PFS and/or OS were not improved with treatment with trilaciclib. Trilaciclib reduces the toxicity of chemotherapy in SCLC." Butler noted.

The North Carolina-based biopharma's second asset in clinical development is rintodestrant. It is an oral, selective estrogen receptor degrader (SERD), for estrogen receptor (ER) positive, HER2 negative breast cancer. "An oral SERD that can rapidly reach steady state, may have utility in ER positive breast cancer," Butler wrote. This is based on the fact that the combination of fulvestrant, an intramuscular SERD, and palbociclib is a proven therapeutic in the indication. Fulvestrant, which was approved in 2002, attained blockbuster status in 2018, but it is associated with "poor physiochemical properties that require monthly injections leading to less than optimal activity."

With an estimated market size of ER positive, HER2 negative advanced/metastatic breast cancer patients in the U.S and Europe, ROTH projects peak revenue from both places of $2.1 billion. It projects a rintodestrant launch in 2025-2026.

G1's third asset is lerociclib, which is also a CDK4/6 inhibitor and which the company is looking to outlicense and market in Europe with a partner, as a treatment for small cell lung, triple-negative breast and colorectal cancers. Recently, G1 entered an exclusive licensing agreement for lerociclib in the Asia-Pacific region, excluding Japan, with Genor Biopharma, a Chinese biopharma.

Finally, Butler reviewed G1 Therapeutics' financial situation. The company had $242.4 million in cash and cash equivalents at the end of March 2020. Also, it recently entered an agreement with Hercules Capital for up to $100 million in funding for commercialization and further advancement of trilaciclib. The agreement calls for payments to G1 in four tranches, the first of which is $30 million, to be paid upon closing. G1 will receive the remaining tranches when it completes certain milestones.

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from ROTH Capital Partners, G1 Therapeutics, Inc., Company Note, June 26, 2020

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

ROTH makes a market in shares of G1 Therapeutics, Inc. and as such, buys and sells from customers on a principal basis.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.

{{labelSign}}  Favorites

Get the latest news and updates from Stockhouse on social media


Featured Company